{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:59:36Z","timestamp":1780343976422,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Province Natural Science Foundation of China","award":["LTGY23H180012"],"award-info":[{"award-number":["LTGY23H180012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-025-01751-9","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:27:02Z","timestamp":1751358422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["MRI radiomics model for predicting tumor immune microenvironment types and efficacy of anti-PD-1\/PD-L1 therapy in hepatocellular carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Rui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"1751_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209\u201349.","journal-title":"Cancer J Clin"},{"key":"1751_CR2","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389:2492\u2013502.","journal-title":"Lancet"},{"key":"1751_CR3","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jamaoncol.2016.2450","volume":"2","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Chen L. Classification of advanced human cancers based on tumor immunity in the microenvironment (TIME) for Cancer immunotherapy. JAMA Oncol. 2016;2:1403.","journal-title":"JAMA Oncol"},{"key":"1751_CR4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3748\/wjg.v29.i6.1054","volume":"29","author":"DS Mandlik","year":"2023","unstructured":"Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol. 2023;29:1054\u201375.","journal-title":"World J Gastroenterol"},{"key":"1751_CR5","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau T, Kang Y-K, Kim T-Y, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib. JAMA Oncol. 2020;6:e204564.","journal-title":"JAMA Oncol"},{"key":"1751_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park J-W, Finn RS, Cheng A-L, Mathurin P, Edeline J, et al. Nivolumab versus Sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23:77\u201390.","journal-title":"Lancet Oncol"},{"key":"1751_CR7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"1751_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000516899","volume":"10","author":"M Morita","year":"2021","unstructured":"Morita M, Nishida N, Sakai K, Aoki T, Hirokazu Chishina, Takita M, et al. Immunological microenvironment predicts the survival of the patients with hepatocellular carcinoma treated with Anti-PD-1 antibody. Liver Cancer. 2021;10:380\u201393.","journal-title":"Liver Cancer"},{"key":"1751_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","volume":"612","author":"R Xue","year":"2022","unstructured":"Xue R, Zhang Q, Cao Q, Kong R, Xiang X, Liu H, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022;612:141\u20137.","journal-title":"Nature"},{"key":"1751_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13045-021-01167-2","volume":"14","author":"R Gao","year":"2021","unstructured":"Gao R, Zhao S, Aishanjiang K, Cai H, Wei T, Zhang Y, et al. Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data. J Hematol Oncol. 2021;14:154.","journal-title":"J Hematol Oncol"},{"key":"1751_CR11","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1158\/1078-0432.CCR-18-2861","volume":"25","author":"S Kim","year":"2019","unstructured":"Kim S, Shin J, Kim D-Y, Choi GH, Kim M-J, Choi J-Y. Radiomics on Gadoxetic Acid\u2013Enhanced magnetic resonance imaging for prediction of postoperative early and late recurrence of single hepatocellular carcinoma. Clin Cancer Res. 2019;25:3847\u201355.","journal-title":"Clin Cancer Res"},{"key":"1751_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00330-018-5482-3","volume":"29","author":"L-F Wu","year":"2019","unstructured":"Wu L-F, Rao S-X, Xu P-J, Yang L, Chen C-Z, Liu H, et al. Pre-TACE kurtosis of adctotal derived from histogram analysis for diffusion-weighted imaging is the best independent predictor of prognosis in hepatocellular carcinoma. Eur Radiol. 2019;29:213\u201323.","journal-title":"Eur Radiol"},{"key":"1751_CR13","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1245\/s10434-019-07815-9","volume":"26","author":"H Liao","year":"2019","unstructured":"Liao H, Zhang Z, Chen J, Liao M, Xu L, Wu Z, et al. Preoperative radiomic approach to evaluate Tumor-Infiltrating\u2002CD8(+)\u2002T\u2002Cells\u2002in hepatocellular carcinoma patients using Contrast-Enhanced computed tomography. Ann Surg Oncol. 2019;26:4537\u201347.","journal-title":"Ann Surg Oncol"},{"key":"1751_CR14","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3390\/diagnostics11101875","volume":"11","author":"Y Tian","year":"2021","unstructured":"Tian Y, Komolafe TE, Zheng J, Zhou G, Chen T, Zhou B, et al. Assessing PD-L1 expression level\u2002via preoperative MRI in HCC based on integrating deep learning and radiomics features. Diagnostics (Basel). 2021;11:1875.","journal-title":"Diagnostics (Basel)"},{"key":"1751_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12938-021-00927-y","volume":"21","author":"Q Wang","year":"2022","unstructured":"Wang Q, Dong Y, Xiao T, Zhang S, Yu J, Li L, et al. Prediction of programmed cell death protein 1 in hepatocellular carcinoma patients using radiomics analysis with radiofrequency-based ultrasound multifeature maps. Biomed Eng Online. 2022;21:24.","journal-title":"Biomed Eng Online"},{"key":"1751_CR16","doi-asserted-by":"publisher","first-page":"7710","DOI":"10.1038\/s41598-023-34763-y","volume":"13","author":"XQ Gong","year":"2023","unstructured":"Gong XQ, Liu N, Tao YY, Li L, Li ZM, et al. Radiomics models based on multisequence mri\u2002for predicting PD-1\/PD-L1 expression in hepatocellular carcinoma. Sci Rep. 2023;13:7710.","journal-title":"Sci Rep"},{"key":"1751_CR17","doi-asserted-by":"publisher","first-page":"1435668","DOI":"10.3389\/fimmu.2025.1435668","volume":"16","author":"G Hapaer","year":"2025","unstructured":"Hapaer G, Che F, Xu Q, Li Q, Liang A, Wang Z, et al. Radiomics-based biomarker for PD-1\u2002status and prognosis analysis in patients with HCC. Front Immunol. 2025;16:1435668.","journal-title":"Front Immunol"},{"key":"1751_CR18","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1007\/s00330-018-5986-x","volume":"29","author":"S Chen","year":"2019","unstructured":"Chen S, Feng S, Wei J, Liu F, Li B, Li X, et al. Pretreatment prediction of immunoscore in\u2002hepatocellular\u2002cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging. Eur Radiol. 2019;29:4177\u201387.","journal-title":"Eur Radiol"},{"key":"1751_CR19","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68:723\u201350.","journal-title":"Hepatology"},{"key":"1751_CR20","doi-asserted-by":"crossref","unstructured":"Huang C, Zhu X-D, Shen Y-H, Wu D, Ji Y, Ge N-L et al. Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomark Res. 2021;9.","DOI":"10.1186\/s40364-021-00274-z"},{"key":"1751_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1751_CR22","doi-asserted-by":"publisher","first-page":"10685","DOI":"10.1007\/s00432-023-04949-y","volume":"149","author":"P kong","year":"2023","unstructured":"Kong P, Yang H, Tong Q, Dong X, Yi M-A, Yan D. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model. J Cancer Res Clin Oncol. 2023;149:10685\u2013700.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1751_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41416-018-0144-4","volume":"119","author":"C Liu","year":"2018","unstructured":"Liu C, Xu J, Zhou Z, Jin L-L, Yu X-J, Xiao G, et al. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. Br J Cancer. 2018;119:80\u20138.","journal-title":"Br J Cancer"},{"key":"1751_CR24","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940\u201352.","journal-title":"Lancet Oncol"},{"key":"1751_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-024-00747-z","volume":"11","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Chen X, Feng L, Yang Z, Xiao L, Xiang B, et al. Stromal architecture and fibroblast subpopulations with opposing effects on outcomes in hepatocellular carcinoma. Cell Discov. 2025;11:1.","journal-title":"Cell Discov"},{"key":"1751_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/bs.acr.2015.05.001","volume":"128","author":"JD Peske","year":"2015","unstructured":"Peske JD, Woods AB, Engelhard VH. Control of CD8 T-Cell infiltration into tumors by vasculature\u2002and\u2002microenvironment. Adv Cancer Res. 2015;128:263\u2013307.","journal-title":"Adv Cancer Res"},{"key":"1751_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/ATVBAHA.123.319101","volume":"43","author":"KJ Bayless","year":"2023","unstructured":"Bayless KJ. Direct involvement of CD8(+) T cells in retinal angiogenesis. Arterioscler Thromb Vasc Biol. 2023;43:537\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1751_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12885-023-10733-5","volume":"23","author":"X Liu","year":"2023","unstructured":"Liu X, Li Z, Sun J, Zhang Z, Li W. Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages. BMC Cancer. 2023;23:259.","journal-title":"BMC Cancer"},{"key":"1751_CR29","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.2147\/JHC.S478604","volume":"11","author":"X Shen","year":"2024","unstructured":"Shen X, Zhang J-X, Liu J, Liu S, Shi H-B, Cheng Y, et al. Efficacy of Atezolizumab plus bevacizumab combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: A Real-World study. J Hepatocellular Carcinoma. 2024;11:1993\u20132003.","journal-title":"J Hepatocellular Carcinoma"},{"key":"1751_CR30","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/cancers13071607","volume":"13","author":"H-C Hung","year":"2021","unstructured":"Hung H-C, Lee J-C, Wang Y-C, Cheng C-H, Wu T-H, Lee C-F, et al. Response prediction in immune checkpoint inhibitor immunotherapy for advanced hepatocellular carcinoma. Cancers. 2021;13:1607.","journal-title":"Cancers"},{"key":"1751_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1159\/000528034","volume":"12","author":"B Xu","year":"2022","unstructured":"Xu B, Dong S-Y, Bai X-L, Song T-Q, Zhang B-H, Zhou L-D, et al. Tumor radiomic features on pretreatment MRI to predict response to lenvatinib plus an Anti-PD-1 antibody in advanced hepatocellular carcinoma: A multicenter study. Liver Cancer. 2022;12:262\u201376.","journal-title":"Liver Cancer"},{"key":"1751_CR32","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.crad.2022.09.113","volume":"78","author":"H Cui","year":"2022","unstructured":"Cui H, Zeng L, Li R, Li Q, Hong C, Zhu H, et al. Radiomics signature based on CECT for non-invasive prediction of response to anti-PD-1 therapy in patients with hepatocellular carcinoma. Clin Radiol. 2022;78:e37\u201344.","journal-title":"Clin Radiol"},{"key":"1751_CR33","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","volume":"89","author":"LM Forrest","year":"2003","unstructured":"Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89:1028\u201330.","journal-title":"Br J Cancer"},{"key":"1751_CR34","doi-asserted-by":"publisher","first-page":"108113","DOI":"10.1016\/j.cmpb.2024.108113","volume":"248","author":"S Contino","year":"2024","unstructured":"Contino S, Cruciata L, Gambino O, Pirrone R. IODeep: an IOD for the introduction of deep\u2002learning\u2002in the DICOM standard. Comput Methods Programs Biomed. 2024;248:108113.","journal-title":"Comput Methods Programs Biomed"},{"key":"1751_CR35","doi-asserted-by":"publisher","first-page":"e0000227","DOI":"10.1371\/journal.pdig.0000227","volume":"2","author":"JR Hawkins","year":"2023","unstructured":"Hawkins JR, Olson MP, Harouni A, Qin MM, Hess CP, Majumdar S, et al. Implementation and prospective real-time evaluation of a generalized\u2002system\u2002for in-clinic deployment and validation of\u2002machine\u2002learning\u2002models\u2002in radiology. PLOS Digit Health. 2023;2:e0000227.","journal-title":"PLOS Digit Health"},{"key":"1751_CR36","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s10278-020-00348-8","volume":"33","author":"JH Sohn","year":"2020","unstructured":"Sohn JH, Chillakuru YR, Lee S, Lee AY, Kelil T, Hess CP, et al. An Open-Source, Vender agnostic hardware and software pipeline for\u2002integration\u2002of artificial intelligence in radiology workflow. J Digit Imaging. 2020;33:1041\u20136.","journal-title":"J Digit Imaging"},{"key":"1751_CR37","doi-asserted-by":"publisher","first-page":"107601","DOI":"10.1016\/j.jmr.2023.107601","volume":"358","author":"X Chen","year":"2024","unstructured":"Chen X, Li J, Chen D, Zhou Y, Tu Z, Lin M, et al. CloudBrain-MRS: an intelligent cloud computing platform for in vivo magnetic resonance spectroscopy preprocessing, quantification, and analysis. J Magn Reson. 2024;358:107601.","journal-title":"J Magn Reson"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01751-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-025-01751-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01751-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:27:05Z","timestamp":1751358425000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-025-01751-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1751"],"URL":"https:\/\/doi.org\/10.1186\/s12880-025-01751-9","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University (Reference Number: 2023\u2009\u2212\u20091017) and all patient information was used anonymously. Given the retrospective nature of the study, the requirement for informed consent was waived. All methods were carried out in accordance with relevant guidelines and regulations or the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}